ID   AMPN_HUMAN              Reviewed;         967 AA.
AC   P15144; Q16728; Q6GT90; Q8IUK3; Q8IVH3; Q9UCE0;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 4.
DT   10-MAY-2017, entry version 201.
DE   RecName: Full=Aminopeptidase N {ECO:0000305};
DE            Short=AP-N;
DE            Short=hAPN;
DE            EC=3.4.11.2 {ECO:0000269|PubMed:22932899, ECO:0000269|PubMed:6149934, ECO:0000269|PubMed:7576235, ECO:0000269|PubMed:8887485};
DE   AltName: Full=Alanyl aminopeptidase;
DE   AltName: Full=Aminopeptidase M;
DE            Short=AP-M;
DE   AltName: Full=Microsomal aminopeptidase;
DE   AltName: Full=Myeloid plasma membrane glycoprotein CD13;
DE   AltName: Full=gp150;
DE   AltName: CD_antigen=CD13;
GN   Name=ANPEP; Synonyms=APN, CD13, PEPN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLN-86 AND MET-603.
RC   TISSUE=Intestine;
RX   PubMed=2901990; DOI=10.1016/0014-5793(88)80502-7;
RA   Olsen J., Cowell G.M., Koenigshoefer E., Danielsen E.M., Moeller J.,
RA   Laustsen L., Hansen O.C., Welinder K.G., Engberg J., Hunziker W.,
RA   Spiess M., Sjoestroem H., Noren O.;
RT   "Complete amino acid sequence of human intestinal aminopeptidase N as
RT   deduced from cloned cDNA.";
RL   FEBS Lett. 238:307-314(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 2-21, VARIANT GLN-86,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=2564851; DOI=10.1172/JCI114015;
RA   Look A.T., Ashmun R.A., Shapiro L.H., Peiper S.C.;
RT   "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical
RT   to aminopeptidase N.";
RL   J. Clin. Invest. 83:1299-1307(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.
RC   TISSUE=Intestinal epithelium;
RX   PubMed=1675638;
RA   Shapiro L.H., Ashmun R.A., Roberts W.M., Look A.T.;
RT   "Separate promoters control transcription of the human aminopeptidase
RT   N gene in myeloid and intestinal epithelial cells.";
RL   J. Biol. Chem. 266:11999-12007(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-479 AND 524-967, AND VARIANT
RP   GLN-86.
RC   TISSUE=Peripheral blood;
RA   Eiz-Vesper B., Fuchs N., Gottschalk D., Mueller K., Reuter S.,
RA   Blasczyk R.;
RT   "Genomic organisation of aminopeptidase N.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PROTEIN SEQUENCE OF 2-20 AND 70-81, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=7576235; DOI=10.1515/bchm3.1995.376.7.397;
RA   Watanabe Y., Iwaki-Egawa S., Mizukoshi H., Fujimoto Y.;
RT   "Identification of an alanine aminopeptidase in human maternal serum
RT   as a membrane-bound aminopeptidase N.";
RL   Biol. Chem. Hoppe-Seyler 376:397-400(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-18, AND FUNCTION.
RX   PubMed=8102610; DOI=10.1016/0014-5793(93)80199-5;
RA   Nunez L., Amigo L., Rigotti A., Puglielli L., Mingrone G., Greco A.V.,
RA   Nervi F.;
RT   "Cholesterol crystallization-promoting activity of aminopeptidase-N
RT   isolated from the vesicular carrier of biliary lipids.";
RL   FEBS Lett. 329:84-88(1993).
RN   [9]
RP   CATALYTIC ACTIVITY, CHARACTERIZATION, AND SUBUNIT.
RX   PubMed=6149934;
RA   Tokioka-Terao M., Hiwada K., Kokubu T.;
RT   "Purification and characterization of aminopeptidase N from human
RT   plasma.";
RL   Enzyme 32:65-75(1984).
RN   [10]
RP   GLYCOSYLATION.
RX   PubMed=1705556;
RA   O'Connell P.J., Gerkis V., d'Apice A.J.F.;
RT   "Variable O-glycosylation of CD13 (aminopeptidase N).";
RL   J. Biol. Chem. 266:4593-4597(1991).
RN   [11]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HCOV-229E SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION), AND TOPOLOGY.
RX   PubMed=1350662; DOI=10.1038/357420a0;
RA   Yeager C.L., Ashmun R.A., Williams R.K., Cardellichio C.B.,
RA   Shapiro L.H., Look A.T., Holmes K.V.;
RT   "Human aminopeptidase N is a receptor for human coronavirus 229E.";
RL   Nature 357:420-422(1992).
RN   [12]
RP   IDENTIFICATION OF SOLUBLE FORM, AND TISSUE SPECIFICITY.
RX   PubMed=7902291;
RA   Favaloro E.J., Browning T., Facey D.;
RT   "CD13 (GP150; aminopeptidase-N): predominant functional activity in
RT   blood is localized to plasma and is not cell-surface associated.";
RL   Exp. Hematol. 21:1695-1701(1993).
RN   [13]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=8105105;
RA   Soderberg C., Giugni T.D., Zaia J.A., Larsson S., Wahlberg J.M.,
RA   Moller E.;
RT   "CD13 (human aminopeptidase N) mediates human cytomegalovirus
RT   infection.";
RL   J. Virol. 67:6576-6585(1993).
RN   [14]
RP   CATALYTIC ACTIVITY, FUNCTION (MICROBIAL INFECTION), INTERACTION WITH
RP   HCOV-229E SPIKE GLYCOPROTEIN (MICROBIAL INFECTION), REGION, AND
RP   MUTAGENESIS OF HIS-392.
RX   PubMed=8887485; DOI=10.1099/0022-1317-77-10-2515;
RA   Kolb A.F., Maile J., Heister A., Siddell S.G.;
RT   "Characterization of functional domains in the human coronavirus HCV
RT   229E receptor.";
RL   J. Gen. Virol. 77:2515-2521(1996).
RN   [15]
RP   FUNCTION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9056417; DOI=10.1006/excr.1996.3455;
RA   Noren K., Hansen G.H., Clausen H., Noren O., Sjostrom H., Vogel L.K.;
RT   "Defectively N-glycosylated and non-O-glycosylated aminopeptidase N
RT   (CD13) is normally expressed at the cell surface and has full
RT   enzymatic activity.";
RL   Exp. Cell Res. 231:112-118(1997).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HCOV-229E SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION), AND REGION.
RX   PubMed=9367365;
RA   Kolb A.F., Hegyi A., Siddell S.G.;
RT   "Identification of residues critical for the human coronavirus 229E
RT   receptor function of human aminopeptidase N.";
RL   J. Gen. Virol. 78:2795-2802(1997).
RN   [17]
RP   FUNCTION, AND ENZYMATIC CLEAVAGE OF ANTIGEN PEPTIDES BOUND TO CLASS II
RP   MHC.
RX   PubMed=10605003; DOI=10.4049/jimmunol.164.1.129;
RA   Dong X., An B., Salvucci Kierstead L., Storkus W.J., Amoscato A.A.,
RA   Salter R.D.;
RT   "Modification of the amino terminus of a class II epitope confers
RT   resistance to degradation by CD13 on dendritic cells and enhances
RT   presentation to T cells.";
RL   J. Immunol. 164:129-135(2000).
RN   [18]
RP   ROLE IN ANGIOGENESIS, AND CHARACTERIZATION OF RECEPTOR FOR
RP   TUMOR-HOMING PEPTIDES FUNCTION.
RX   PubMed=10676659;
RA   Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M.,
RA   Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E.;
RT   "Aminopeptidase N is a receptor for tumor-homing peptides and a target
RT   for inhibiting angiogenesis.";
RL   Cancer Res. 60:722-727(2000).
RN   [19]
RP   FUNCTION, AND INDUCTION BY ESTRADIOL AND IL8.
RX   PubMed=11384645; DOI=10.1016/S0015-0282(01)01779-4;
RA   Seli E., Senturk L.M., Bahtiyar O.M., Kayisli U.A., Arici A.;
RT   "Expression of aminopeptidase N in human endometrium and regulation of
RT   its activity by estrogen.";
RL   Fertil. Steril. 75:1172-1176(2001).
RN   [20]
RP   MUTAGENESIS OF 288-ASP--SER-295 AND ASN-818.
RX   PubMed=11559807; DOI=10.1128/JVI.75.20.9741-9752.2001;
RA   Wentworth D.E., Holmes K.V.;
RT   "Molecular determinants of species specificity in the coronavirus
RT   receptor aminopeptidase N (CD13): influence of N-linked
RT   glycosylation.";
RL   J. Virol. 75:9741-9752(2001).
RN   [21]
RP   FUNCTION OF SOLUBLE FORM.
RX   PubMed=12473585;
RA   van Hensbergen Y., Broxterman H.J., Hanemaaijer R., Jorna A.S.,
RA   van Lent N.A., Verheul H.M., Pinedo H.M., Hoekman K.;
RT   "Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions
RT   and intratumoral fluid.";
RL   Clin. Cancer Res. 8:3747-3754(2002).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HCOV-229E SPIKE
RP   GLYCOPROTEIN.
RX   PubMed=12551991; DOI=10.1128/JVI.77.4.2530-2538.2003;
RA   Bonavia A., Zelus B.D., Wentworth D.E., Talbot P.J., Holmes K.V.;
RT   "Identification of a receptor-binding domain of the spike glycoprotein
RT   of human coronavirus HCoV-229E.";
RL   J. Virol. 77:2530-2538(2003).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-265.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-128; ASN-234; ASN-265;
RP   ASN-681 AND ASN-818.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-128; ASN-234; ASN-265;
RP   ASN-573; ASN-681 AND ASN-818.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 66-967 IN COMPLEX WITH
RP   ANGIOTENSIN-4 AND INHIBITORS, CATALYTIC ACTIVITY, COFACTOR,
RP   SUBSTRATE-BINDING REGION, ZINC-BINDING SITES, ACTIVE SITE,
RP   GLYCOSYLATION AT ASN-128; ASN-234; ASN-265; ASN-319; ASN-527; ASN-625;
RP   ASN-681 AND ASN-818, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=22932899; DOI=10.1074/jbc.M112.398842;
RA   Wong A.H., Zhou D., Rini J.M.;
RT   "The X-ray crystal structure of human aminopeptidase N reveals a novel
RT   dimer and the basis for peptide processing.";
RL   J. Biol. Chem. 287:36804-36813(2012).
RN   [30]
RP   VARIANTS TYR-242 AND PRO-243.
RX   PubMed=9452074;
RA   Lendeckel U., Wex T., Arndt M., Frank K., Franke A., Ansorge S.;
RT   "Identification of point mutations in the aminopeptidase N gene by
RT   SSCP analysis and sequencing.";
RL   Hum. Mutat. Suppl. 1:S158-S160(1998).
CC   -!- FUNCTION: Broad specificity aminopeptidase which plays a role in
CC       the final digestion of peptides generated from hydrolysis of
CC       proteins by gastric and pancreatic proteases. Also involved in the
CC       processing of various peptides including peptide hormones, such as
CC       angiotensin III and IV, neuropeptides, and chemokines. May also be
CC       involved the cleavage of peptides bound to major
CC       histocompatibility complex class II molecules of antigen
CC       presenting cells. May have a role in angiogenesis and promote
CC       cholesterol crystallization. {ECO:0000269|PubMed:10605003,
CC       ECO:0000269|PubMed:10676659, ECO:0000269|PubMed:11384645,
CC       ECO:0000269|PubMed:12473585, ECO:0000269|PubMed:7576235,
CC       ECO:0000269|PubMed:8102610, ECO:0000269|PubMed:9056417}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for human
CC       coronavirus 229E/HCoV-229E. In case of human coronavirus 229E
CC       (HCoV-229E) infection, serves as receptor for HCoV-229E spike
CC       glycoprotein (PubMed:1350662, PubMed:8887485, PubMed:9367365,
CC       PubMed:12551991). Mediates as well human cytomegalovirus (HCMV)
CC       infection (PubMed:8105105). {ECO:0000269|PubMed:12551991,
CC       ECO:0000269|PubMed:1350662, ECO:0000269|PubMed:8105105,
CC       ECO:0000269|PubMed:8887485, ECO:0000269|PubMed:9367365}.
CC   -!- CATALYTIC ACTIVITY: Release of an N-terminal amino acid, Xaa-|-
CC       Yaa- from a peptide, amide or arylamide. Xaa is preferably Ala,
CC       but may be most amino acids including Pro (slow action). When a
CC       terminal hydrophobic residue is followed by a prolyl residue, the
CC       two may be released as an intact Xaa-Pro dipeptide.
CC       {ECO:0000269|PubMed:22932899, ECO:0000269|PubMed:6149934,
CC       ECO:0000269|PubMed:7576235, ECO:0000269|PubMed:8887485}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:22932899};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:22932899};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:22932899,
CC       ECO:0000269|PubMed:6149934}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with the S1 domain of
CC       human coronavirus 229E/HCoV-229E spike protein.
CC       {ECO:0000269|PubMed:12551991, ECO:0000269|PubMed:1350662,
CC       ECO:0000269|PubMed:8887485}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:2564851,
CC       ECO:0000269|PubMed:9056417}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:1350662}. Note=Also found as a soluble form.
CC       {ECO:0000269|PubMed:7902291}.
CC   -!- TISSUE SPECIFICITY: Expressed in epithelial cells of the kidney,
CC       intestine, and respiratory tract; granulocytes, monocytes,
CC       fibroblasts, endothelial cells, cerebral pericytes at the blood-
CC       brain barrier, synaptic membranes of cells in the CNS. Also
CC       expressed in endometrial stromal cells, but not in the endometrial
CC       glandular cells. Found in the vasculature of tissues that undergo
CC       angiogenesis and in malignant gliomas and lymph node metastases
CC       from multiple tumor types but not in blood vessels of normal
CC       tissues. A soluble form has been found in plasma. It is found to
CC       be elevated in plasma and effusions of cancer patients.
CC       {ECO:0000269|PubMed:7902291}.
CC   -!- INDUCTION: Estradiol and IL8/interleukin-8 decrease enzymatic
CC       activity in vitro in endometrial stromal cells by 40% and 30%,
CC       respectively. {ECO:0000269|PubMed:11384645}.
CC   -!- PTM: Sulfated. {ECO:0000250|UniProtKB:P15145}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:15084671,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:1705556,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:22932899,
CC       ECO:0000269|PubMed:9056417}.
CC   -!- PTM: May undergo proteolysis and give rise to a soluble form.
CC       {ECO:0000269|PubMed:7902291}.
CC   -!- MISCELLANEOUS: Found to serve as a receptor for tumor-homing
CC       peptides, more specifically NGR peptides. It could serve thus as a
CC       target for delivering drugs into tumors. Concentration in human
CC       hepatic bile, varies from 17.3 to 57.6 micrograms/ml.
CC       {ECO:0000269|PubMed:10676659}.
CC   -!- SIMILARITY: Belongs to the peptidase M1 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13276; CAA31640.1; -; mRNA.
DR   EMBL; M22324; AAA51719.1; -; mRNA.
DR   EMBL; AC018988; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079075; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC058928; AAH58928.1; -; mRNA.
DR   EMBL; M55522; AAA83399.1; -; Genomic_DNA.
DR   EMBL; AJ421875; CAD19098.2; -; Genomic_DNA.
DR   EMBL; AJ421876; CAD19098.2; JOINED; Genomic_DNA.
DR   EMBL; AJ426050; CAD19802.1; -; Genomic_DNA.
DR   EMBL; AJ427985; CAD20931.1; -; Genomic_DNA.
DR   EMBL; AJ427986; CAD20931.1; JOINED; Genomic_DNA.
DR   EMBL; AJ427987; CAD20931.1; JOINED; Genomic_DNA.
DR   EMBL; AJ427988; CAD20931.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS10356.1; -.
DR   PIR; A30325; A30325.
DR   RefSeq; NP_001141.2; NM_001150.2.
DR   RefSeq; XP_005254949.1; XM_005254892.4.
DR   RefSeq; XP_011519775.1; XM_011521473.1.
DR   UniGene; Hs.1239; -.
DR   PDB; 4FYQ; X-ray; 1.90 A; A=66-967.
DR   PDB; 4FYR; X-ray; 1.91 A; A=66-967.
DR   PDB; 4FYS; X-ray; 2.01 A; A=66-967.
DR   PDB; 4FYT; X-ray; 1.85 A; A=66-967.
DR   PDBsum; 4FYQ; -.
DR   PDBsum; 4FYR; -.
DR   PDBsum; 4FYS; -.
DR   PDBsum; 4FYT; -.
DR   ProteinModelPortal; P15144; -.
DR   SMR; P15144; -.
DR   BioGrid; 106787; 2.
DR   IntAct; P15144; 5.
DR   STRING; 9606.ENSP00000300060; -.
DR   BindingDB; P15144; -.
DR   ChEMBL; CHEMBL1907; -.
DR   DrugBank; DB00973; Ezetimibe.
DR   DrugBank; DB06196; Icatibant.
DR   GuidetoPHARMACOLOGY; 1560; -.
DR   MEROPS; M01.001; -.
DR   iPTMnet; P15144; -.
DR   PhosphoSitePlus; P15144; -.
DR   SwissPalm; P15144; -.
DR   UniCarbKB; P15144; -.
DR   BioMuta; ANPEP; -.
DR   DMDM; 143811362; -.
DR   EPD; P15144; -.
DR   MaxQB; P15144; -.
DR   PaxDb; P15144; -.
DR   PeptideAtlas; P15144; -.
DR   PRIDE; P15144; -.
DR   DNASU; 290; -.
DR   Ensembl; ENST00000300060; ENSP00000300060; ENSG00000166825.
DR   GeneID; 290; -.
DR   KEGG; hsa:290; -.
DR   UCSC; uc002bop.5; human.
DR   CTD; 290; -.
DR   DisGeNET; 290; -.
DR   GeneCards; ANPEP; -.
DR   H-InvDB; HIX0038141; -.
DR   HGNC; HGNC:500; ANPEP.
DR   HPA; CAB002417; -.
DR   HPA; HPA004625; -.
DR   MIM; 151530; gene.
DR   neXtProt; NX_P15144; -.
DR   OpenTargets; ENSG00000166825; -.
DR   PharmGKB; PA24815; -.
DR   eggNOG; KOG1046; Eukaryota.
DR   eggNOG; COG0308; LUCA.
DR   GeneTree; ENSGT00760000119082; -.
DR   HOVERGEN; HBG006616; -.
DR   InParanoid; P15144; -.
DR   KO; K11140; -.
DR   OMA; QISEMFD; -.
DR   OrthoDB; EOG091G01GH; -.
DR   PhylomeDB; P15144; -.
DR   TreeFam; TF300395; -.
DR   BRENDA; 3.4.11.2; 2681.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P15144; -.
DR   SIGNOR; P15144; -.
DR   ChiTaRS; ANPEP; human.
DR   GeneWiki; Alanine_aminopeptidase; -.
DR   GenomeRNAi; 290; -.
DR   PRO; PR:P15144; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000166825; -.
DR   CleanEx; HS_ANPEP; -.
DR   ExpressionAtlas; P15144; baseline and differential.
DR   Genevisible; P15144; HS.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0004177; F:aminopeptidase activity; TAS:ProtInc.
DR   GO; GO:0070006; F:metalloaminopeptidase activity; IBA:GO_Central.
DR   GO; GO:0008237; F:metallopeptidase activity; TAS:ProtInc.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007267; P:cell-cell signaling; IBA:GO_Central.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0043171; P:peptide catabolic process; IBA:GO_Central.
DR   GO; GO:0008217; P:regulation of blood pressure; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   CDD; cd09601; M1_APN_2; 1.
DR   InterPro; IPR024571; ERAP1-like_C_dom.
DR   InterPro; IPR034016; M1_APN-typ.
DR   InterPro; IPR001930; Peptidase_M1.
DR   InterPro; IPR014782; Peptidase_M1_N.
DR   PANTHER; PTHR11533; PTHR11533; 1.
DR   Pfam; PF11838; ERAP1_C; 1.
DR   Pfam; PF01433; Peptidase_M1; 1.
DR   PRINTS; PR00756; ALADIPTASE.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Aminopeptidase; Angiogenesis; Cell membrane;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Hydrolase;
KW   Membrane; Metal-binding; Metalloprotease; Polymorphism; Protease;
KW   Receptor; Reference proteome; Signal-anchor; Sulfation; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:2564851,
FT                                ECO:0000269|PubMed:7576235,
FT                                ECO:0000269|PubMed:8102610}.
FT   CHAIN         2    967       Aminopeptidase N.
FT                                /FTId=PRO_0000095081.
FT   TOPO_DOM      2      8       Cytoplasmic.
FT                                {ECO:0000305|PubMed:1350662}.
FT   TRANSMEM      9     32       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     33    967       Extracellular.
FT                                {ECO:0000269|PubMed:1350662}.
FT   REGION       33     68       Cytosolic Ser/Thr-rich junction.
FT   REGION       69    967       Metalloprotease.
FT   REGION      288    295       Necessary and sufficient to mediate
FT                                interaction with HCoV-229E.
FT                                {ECO:0000269|PubMed:1350662,
FT                                ECO:0000269|PubMed:8887485}.
FT   REGION      352    356       Substrate binding.
FT                                {ECO:0000269|PubMed:22932899}.
FT   ACT_SITE    389    389       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10095,
FT                                ECO:0000269|PubMed:22932899}.
FT   METAL       388    388       Zinc; catalytic. {ECO:0000244|PDB:4FYQ,
FT                                ECO:0000244|PDB:4FYR,
FT                                ECO:0000244|PDB:4FYT,
FT                                ECO:0000269|PubMed:22932899}.
FT   METAL       392    392       Zinc; catalytic. {ECO:0000244|PDB:4FYQ,
FT                                ECO:0000244|PDB:4FYR,
FT                                ECO:0000244|PDB:4FYT,
FT                                ECO:0000269|PubMed:22932899}.
FT   METAL       411    411       Zinc; catalytic. {ECO:0000244|PDB:4FYQ,
FT                                ECO:0000244|PDB:4FYR,
FT                                ECO:0000244|PDB:4FYT,
FT                                ECO:0000269|PubMed:22932899}.
FT   SITE        477    477       Transition state stabilizer.
FT                                {ECO:0000269|PubMed:22932899}.
FT   MOD_RES     176    176       Sulfotyrosine. {ECO:0000255}.
FT   MOD_RES     419    419       Sulfotyrosine. {ECO:0000255}.
FT   MOD_RES     424    424       Sulfotyrosine. {ECO:0000255}.
FT   MOD_RES     913    913       Sulfotyrosine. {ECO:0000255}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    234    234       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:15084671,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    319    319       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    527    527       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    573    573       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    625    625       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    681    681       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22932899}.
FT   CARBOHYD    735    735       N-linked (GlcNAc...) asparagine.
FT   CARBOHYD    818    818       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22932899}.
FT   DISULFID    761    768       {ECO:0000269|PubMed:22932899}.
FT   DISULFID    798    834       {ECO:0000269|PubMed:22932899}.
FT   VARIANT      20     20       V -> M (in dbSNP:rs10152474).
FT                                /FTId=VAR_031262.
FT   VARIANT      86     86       R -> Q (in dbSNP:rs25653).
FT                                {ECO:0000269|PubMed:2564851,
FT                                ECO:0000269|PubMed:2901990,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_014736.
FT   VARIANT     242    242       D -> Y. {ECO:0000269|PubMed:9452074}.
FT                                /FTId=VAR_006727.
FT   VARIANT     243    243       L -> P. {ECO:0000269|PubMed:9452074}.
FT                                /FTId=VAR_006728.
FT   VARIANT     311    311       A -> V (in dbSNP:rs17240268).
FT                                /FTId=VAR_031263.
FT   VARIANT     321    321       T -> M (in dbSNP:rs8179199).
FT                                /FTId=VAR_031264.
FT   VARIANT     603    603       I -> K (in dbSNP:rs17240212).
FT                                /FTId=VAR_031265.
FT   VARIANT     603    603       I -> M (in dbSNP:rs8192297).
FT                                {ECO:0000269|PubMed:2901990}.
FT                                /FTId=VAR_031266.
FT   VARIANT     752    752       S -> N (in dbSNP:rs25651).
FT                                /FTId=VAR_014737.
FT   MUTAGEN     288    295       DYVEKQAS->QSVEETAQ: No change in receptor
FT                                activity and HCoV-229E infection.
FT                                {ECO:0000269|PubMed:11559807}.
FT   MUTAGEN     288    295       DYVEKQAS->QSVNEQAQ: No change in receptor
FT                                activity and HCoV-229E infection.
FT                                {ECO:0000269|PubMed:11559807}.
FT   MUTAGEN     288    295       DYVEKQAS->QSVNETAQ: Complete loss of
FT                                receptor activity and blocks HCoV-229E
FT                                infection. No loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:11559807}.
FT   MUTAGEN     291    293       EKQ->NKT: Complete loss of receptor
FT                                activity and blocks HCoV-229E infection.
FT                                No loss of enzymatic activity.
FT   MUTAGEN     291    291       E->N: No change of receptor activity and
FT                                HCoV-229E infection.
FT   MUTAGEN     293    293       Q->T: No change of receptor activity and
FT                                HCoV-229E infection.
FT   MUTAGEN     392    392       H->A: Loss of aminopeptidase activity.
FT                                {ECO:0000269|PubMed:8887485}.
FT   MUTAGEN     818    818       N->E: Very low receptor activity and
FT                                HCoV-229E infection.
FT                                {ECO:0000269|PubMed:11559807}.
FT   CONFLICT    536    536       V -> E (in Ref. 1; CAA31640).
FT                                {ECO:0000305}.
FT   CONFLICT    887    887       L -> P (in Ref. 1; CAA31640).
FT                                {ECO:0000305}.
FT   HELIX        70     72       {ECO:0000244|PDB:4FYT}.
FT   STRAND       73     75       {ECO:0000244|PDB:4FYT}.
FT   STRAND       78     91       {ECO:0000244|PDB:4FYT}.
FT   STRAND      102    115       {ECO:0000244|PDB:4FYT}.
FT   STRAND      118    123       {ECO:0000244|PDB:4FYT}.
FT   STRAND      135    142       {ECO:0000244|PDB:4FYT}.
FT   STRAND      150    156       {ECO:0000244|PDB:4FYT}.
FT   TURN        157    160       {ECO:0000244|PDB:4FYT}.
FT   STRAND      161    168       {ECO:0000244|PDB:4FYT}.
FT   STRAND      175    185       {ECO:0000244|PDB:4FYT}.
FT   STRAND      188    200       {ECO:0000244|PDB:4FYT}.
FT   STRAND      203    211       {ECO:0000244|PDB:4FYT}.
FT   TURN        213    216       {ECO:0000244|PDB:4FYT}.
FT   HELIX       217    219       {ECO:0000244|PDB:4FYT}.
FT   STRAND      231    240       {ECO:0000244|PDB:4FYT}.
FT   STRAND      243    249       {ECO:0000244|PDB:4FYT}.
FT   STRAND      251    253       {ECO:0000244|PDB:4FYT}.
FT   STRAND      256    258       {ECO:0000244|PDB:4FYT}.
FT   STRAND      261    269       {ECO:0000244|PDB:4FYT}.
FT   HELIX       277    279       {ECO:0000244|PDB:4FYT}.
FT   STRAND      282    285       {ECO:0000244|PDB:4FYT}.
FT   STRAND      288    293       {ECO:0000244|PDB:4FYT}.
FT   STRAND      299    304       {ECO:0000244|PDB:4FYT}.
FT   HELIX       306    310       {ECO:0000244|PDB:4FYT}.
FT   TURN        311    314       {ECO:0000244|PDB:4FYT}.
FT   HELIX       315    331       {ECO:0000244|PDB:4FYT}.
FT   STRAND      338    348       {ECO:0000244|PDB:4FYT}.
FT   STRAND      350    354       {ECO:0000244|PDB:4FYT}.
FT   STRAND      359    363       {ECO:0000244|PDB:4FYT}.
FT   HELIX       364    367       {ECO:0000244|PDB:4FYT}.
FT   TURN        371    373       {ECO:0000244|PDB:4FYT}.
FT   HELIX       376    394       {ECO:0000244|PDB:4FYT}.
FT   TURN        396    398       {ECO:0000244|PDB:4FYT}.
FT   STRAND      399    403       {ECO:0000244|PDB:4FYT}.
FT   HELIX       404    407       {ECO:0000244|PDB:4FYT}.
FT   HELIX       408    425       {ECO:0000244|PDB:4FYT}.
FT   HELIX       427    429       {ECO:0000244|PDB:4FYT}.
FT   HELIX       431    434       {ECO:0000244|PDB:4FYT}.
FT   HELIX       435    438       {ECO:0000244|PDB:4FYT}.
FT   HELIX       440    447       {ECO:0000244|PDB:4FYT}.
FT   HELIX       459    461       {ECO:0000244|PDB:4FYT}.
FT   HELIX       465    470       {ECO:0000244|PDB:4FYT}.
FT   HELIX       474    491       {ECO:0000244|PDB:4FYT}.
FT   HELIX       493    507       {ECO:0000244|PDB:4FYT}.
FT   STRAND      510    512       {ECO:0000244|PDB:4FYT}.
FT   HELIX       514    527       {ECO:0000244|PDB:4FYT}.
FT   HELIX       536    544       {ECO:0000244|PDB:4FYT}.
FT   STRAND      550    555       {ECO:0000244|PDB:4FYT}.
FT   TURN        556    559       {ECO:0000244|PDB:4FYT}.
FT   STRAND      560    565       {ECO:0000244|PDB:4FYT}.
FT   TURN        579    582       {ECO:0000244|PDB:4FYT}.
FT   STRAND      586    588       {ECO:0000244|PDB:4FYT}.
FT   STRAND      590    592       {ECO:0000244|PDB:4FYT}.
FT   STRAND      600    602       {ECO:0000244|PDB:4FYT}.
FT   STRAND      604    608       {ECO:0000244|PDB:4FYT}.
FT   HELIX       610    612       {ECO:0000244|PDB:4FYT}.
FT   STRAND      620    623       {ECO:0000244|PDB:4FYT}.
FT   HELIX       624    626       {ECO:0000244|PDB:4FYT}.
FT   STRAND      631    634       {ECO:0000244|PDB:4FYT}.
FT   HELIX       636    649       {ECO:0000244|PDB:4FYT}.
FT   HELIX       650    652       {ECO:0000244|PDB:4FYT}.
FT   HELIX       655    670       {ECO:0000244|PDB:4FYT}.
FT   HELIX       676    681       {ECO:0000244|PDB:4FYT}.
FT   HELIX       682    688       {ECO:0000244|PDB:4FYT}.
FT   HELIX       692    709       {ECO:0000244|PDB:4FYT}.
FT   HELIX       715    736       {ECO:0000244|PDB:4FYT}.
FT   TURN        737    741       {ECO:0000244|PDB:4FYT}.
FT   HELIX       747    762       {ECO:0000244|PDB:4FYT}.
FT   HELIX       766    781       {ECO:0000244|PDB:4FYT}.
FT   HELIX       790    792       {ECO:0000244|PDB:4FYT}.
FT   HELIX       793    803       {ECO:0000244|PDB:4FYT}.
FT   HELIX       806    817       {ECO:0000244|PDB:4FYT}.
FT   HELIX       822    832       {ECO:0000244|PDB:4FYT}.
FT   HELIX       838    848       {ECO:0000244|PDB:4FYT}.
FT   TURN        851    853       {ECO:0000244|PDB:4FYT}.
FT   HELIX       856    858       {ECO:0000244|PDB:4FYT}.
FT   HELIX       859    868       {ECO:0000244|PDB:4FYT}.
FT   HELIX       872    882       {ECO:0000244|PDB:4FYT}.
FT   HELIX       884    890       {ECO:0000244|PDB:4FYT}.
FT   TURN        891    894       {ECO:0000244|PDB:4FYT}.
FT   HELIX       898    906       {ECO:0000244|PDB:4FYT}.
FT   HELIX       912    924       {ECO:0000244|PDB:4FYT}.
FT   TURN        925    928       {ECO:0000244|PDB:4FYT}.
FT   HELIX       931    933       {ECO:0000244|PDB:4FYT}.
FT   HELIX       934    965       {ECO:0000244|PDB:4FYT}.
SQ   SEQUENCE   967 AA;  109540 MW;  37B6BC1BF0D6B1F2 CRC64;
     MAKGFYISKS LGILGILLGV AAVCTIIALS VVYSQEKNKN ANSSPVASTT PSASATTNPA
     SATTLDQSKA WNRYRLPNTL KPDSYRVTLR PYLTPNDRGL YVFKGSSTVR FTCKEATDVI
     IIHSKKLNYT LSQGHRVVLR GVGGSQPPDI DKTELVEPTE YLVVHLKGSL VKDSQYEMDS
     EFEGELADDL AGFYRSEYME GNVRKVVATT QMQAADARKS FPCFDEPAMK AEFNITLIHP
     KDLTALSNML PKGPSTPLPE DPNWNVTEFH TTPKMSTYLL AFIVSEFDYV EKQASNGVLI
     RIWARPSAIA AGHGDYALNV TGPILNFFAG HYDTPYPLPK SDQIGLPDFN AGAMENWGLV
     TYRENSLLFD PLSSSSSNKE RVVTVIAHEL AHQWFGNLVT IEWWNDLWLN EGFASYVEYL
     GADYAEPTWN LKDLMVLNDV YRVMAVDALA SSHPLSTPAS EINTPAQISE LFDAISYSKG
     ASVLRMLSSF LSEDVFKQGL ASYLHTFAYQ NTIYLNLWDH LQEAVNNRSI QLPTTVRDIM
     NRWTLQMGFP VITVDTSTGT LSQEHFLLDP DSNVTRPSEF NYVWIVPITS IRDGRQQQDY
     WLIDVRAQND LFSTSGNEWV LLNLNVTGYY RVNYDEENWR KIQTQLQRDH SAIPVINRAQ
     IINDAFNLAS AHKVPVTLAL NNTLFLIEER QYMPWEAALS SLSYFKLMFD RSEVYGPMKN
     YLKKQVTPLF IHFRNNTNNW REIPENLMDQ YSEVNAISTA CSNGVPECEE MVSGLFKQWM
     ENPNNNPIHP NLRSTVYCNA IAQGGEEEWD FAWEQFRNAT LVNEADKLRA ALACSKELWI
     LNRYLSYTLN PDLIRKQDAT STIISITNNV IGQGLVWDFV QSNWKKLFND YGGGSFSFSN
     LIQAVTRRFS TEYELQQLEQ FKKDNEETGF GSGTRALEQA LEKTKANIKW VKENKEVVLQ
     WFTENSK
//
